Search
Cefmetazole
go.drugbank.com/drugs/DB00274ApprovedIt has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
Synonyms: (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidMF-300
go.drugbank.com/drugs/DB32060InvestigationalMF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.
Vinpocetine
go.drugbank.com/drugs/DB12131InvestigationalVinpocetine has been investigated for the treatment of Epilepsy.
Categories: Compounds used in a research, industrial, or household settingDitiocarb
go.drugbank.com/drugs/DB02520InvestigationalA chelating agent that has been used to mobilize toxic metals from the tissues of man and experimental animals. It is the main metabolite of DISULFIRAM.
Categories: Compounds used in a research, industrial, or household settingCGC-11047
go.drugbank.com/drugs/DB05722InvestigationalCGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.
Isoflurane
go.drugbank.com/drugs/DB00753ApprovedInvestigationalVet approvedA stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
Stamulumab
go.drugbank.com/drugs/DB05915InvestigationalMYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Human ciliary neurotrophic factor, recombinant (E. coli)
go.drugbank.com/drugs/DB17959ExperimentalHuman ciliary neurotrophic factor, recombinant was investigated for macular telangiectasia in two clinical trials. … The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia
Synonyms: Human ciliary neurotrophic factor, recombinant (E. coli)Olcegepant
go.drugbank.com/drugs/DB04869InvestigationalOlcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks
Patupilone
go.drugbank.com/drugs/DB03010InvestigationalEpothilone B is a 16-membered macrolide that mimics the biological effects of taxol.